The ruling is a blow to the Trump administration and its plan to bring down drug prices. (Photo: Shutterstock)
More than a year after the Department of Health and Human Services finalized a rule that would require drugmakers to include pricing information in TV ads, the rule continues to be mired down in court challenges.
In the latest blow, a three-judge federal appeals court has ruled that the HHS does not have the authority to compel the price disclosures. The decision affirms a previous ruling by a federal judge last summer in response to a lawsuit filed by Merck & Co., Eli Lilly & Co. and Amgen Inc..
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.